A parent forwarding a clinic flyer pauses on the word “Geref” next to a research listing for Sermorelin. The flyer treats the name like a continuous therapy brand. The everyday question is whether that history still maps to what a catalog vial is today.
What FDA historically approved-and later withdrew from the market
Sermorelin acetate is a synthetic fragment of growth-hormone-releasing hormone, commonly described as GHRH(1-29). Under the brand Geref, FDA previously approved presentations for evaluating pituitary GH secretory capacity and, separately, for treating idiopathic GH deficiency in children with growth failure. A 2013 Federal Register determination records that those Geref products were discontinued and that FDA concluded the withdrawals were not for reasons of safety or effectiveness under the agency’s review process for discontinued drugs.
FDA’s orphan-drug listing for sermorelin acetate (Geref) still documents the historical pediatric GH-deficiency designation and marketing approval timeline. Historical approval is not the same as an active, marketed product you can assume is available through ordinary pharmacy channels today.
Diagnostic history versus research-catalog ads
MedlinePlus growth-disorders guidance and endocrine testing overviews point families toward clinician-directed evaluation when height, growth velocity, or hormone concerns arise. Modern adult GH deficiency testing often uses different agents; this site’s Macrilen story covers one FDA-labeled oral adult stimulation option. Sermorelin’s older diagnostic role does not automatically validate a wellness clinic’s “anti-aging Sermorelin protocol” language.
When a research catalog sells Sermorelin as laboratory material, that listing does not restart a discontinued branded therapy, and it does not create a self-directed GH program. Compounded or research presentations also sit outside the old Geref label’s manufacturing and indication controls.
Clinicians evaluating short stature or adult GH deficiency still rely on history, exam, imaging when indicated, and validated stimulation tests chosen for the patient. A discontinued brand name in a flyer does not replace that workup. If someone offers “Sermorelin anti-aging” without documenting a GH-related diagnosis, you are hearing a wellness pitch that sits outside the old Geref labeling story.
What to do with the flyer. Separate three layers: (1) Sermorelin’s historical FDA products and why they left the market, (2) whether any current clinician is using an authorized diagnostic or treatment pathway for a documented GH problem, and (3) whether a research vial photo is being sold as if it were still Geref. For personal growth or fatigue concerns, use primary-care or endocrinology pathways-not catalog screenshots.
Not medical advice.
Sources
- Federal Register 2013: Geref (sermorelin) withdrawal determination
- FDA orphan listing: sermorelin acetate (Geref)
- MedlinePlus: Growth disorders
- NCBI Bookshelf: Growth hormone deficiency overview context
Related reading
- Macrilen: adult GH stimulation testing with an FDA-labeled drink
- Growth hormone for idiopathic short stature: what trials measured
- IGF-1 blood tests: what the number can and cannot say
By The Everyday Brief. AI-assisted drafting with human editorial review. Sources fetched 2026-10-11 PT. Not medical advice.